[Human papillomavirus infections in urology].
Peyrí Rey
E
E
D052685:Alphapapillomavirus / Q000145:classification / Q000302:isolation & purification / Q000472:pathogenicity; D003131:Combined Modality Therapy; D003218:Condylomata Acuminata / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000601:surgery / Q000821:virology; D005260:Female; D005831:Genital Diseases, Female / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000601:surgery / Q000821:virology; D005832:Genital Diseases, Male / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000601:surgery / Q000821:virology; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission; D053918:Papillomavirus Vaccines; D014526:Urethritis / Q000175:diagnosis / Q000453:epidemiology / Q000821:virology*; D014572:Urology
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines